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Abstract
Aims: To conduct a secondary analysis of the SAGE study to evaluate the association
between glycaemic control and patient-reported outcomes (PROs), in adults with
type 1 diabetes (T1DM) across different age groups and regions.
Materials and methods: SAGE was a multinational, cross-sectional, observational
study in adults with T1DM. Data were collected at a single visit, analysed according
to predefined age groups (26-44, 45-64, and ≥65 years), and reported across differ-
ent regions. PRO questionnaires were applied to assess hypoglycaemia fear
(Hypoglycemia Fear Survey-II), diabetes-related distress (Problem Areas In Diabetes
questionnaire), insulin treatment satisfaction (Insulin Treatment Satisfaction Ques-
tionnaire), and diabetes-specific quality of life (QoL; Audit of Diabetes-Dependent
Quality of Life). Multivariable analysis was performed to evaluate the relationship
between glycated haemoglobin (HbA1c) target achievement (<7% and individualised
targets) with PRO scores.
Results: The PRO scores showed relatively low levels of diabetes-related emotional
distress and fear of hypoglycaemia, moderate to high treatment satisfaction, and low
diabetes-related impact on QoL. Results were generally comparable across age
groups with some regional variability. Achievement of the HbA1c <7% target was
associated with less worry about hypoglycaemia, lower diabetes-related emotional
distress, higher insulin treatment satisfaction, and higher QoL. Achievement of
individualised HbA1c targets was associated with lower diabetes-related emotional
distress and higher insulin treatment satisfaction.
Conclusions: Better glycaemic control was most closely associated with low emotional
distress due to diabetes and high patient-reported insulin treatment satisfaction.
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1 | INTRODUCTION
Type 1 diabetes mellitus (T1DM) is a chronic disease, largely self-man-
aged, affecting both physical health and quality of life (QoL).1,2 The
QoL of people living with T1DM is somewhat different from that of
other populations, due to the burden of disease and treatment self-
management, and the associated frequent decision-making required.1
Indeed, QoL in those with T1DM also includes satisfaction, and psy-
chological and health-related well-being, and thus measuring these
patient-reported outcomes (PROs) requires diabetes-specific instru-
ments.1 Such PRO data from people with T1DM across different
global regions and healthcare systems are sparse.
SAGE (Study of Adults' GlycEmia in T1DM) was a multinational,
observational study undertaken to describe glycaemic control and
QoL in adults aged ≥26 years with T1DM, by predefined age groups
and across 17 countries in five regions outside the United States, with
the aim of improving the understanding of T1DM over a person's
lifespan. The results for the glycaemic endpoints have previously been
published and highlight that glycaemic control remains poor in adults
with T1DM.3 Briefly, 24.3% of participants achieved a glycated
haemoglobin (HbA1c) level of <7%, the recommended target for most
non-pregnant adults with diabetes, with a higher proportion of
achievement in those aged 26 to 44 years (27.6%) than those aged
45 to 64 years (21.0%) and 65 years or above (22.8%).3 However,
American Diabetes Association guidelines recommend glycaemic tar-
gets should be individualised based on several factors, including
patient preference, hypoglycaemia risk, comorbidities, life expectancy
and age.4 In SAGE, all participants were set individualised HbA1c tar-
gets by the treating physician; targets were between 7.0% and 7.5%
in the majority of participants (55.9%) and were achieved by 20.9% of
participants overall.3 Compared with the younger age groups, a higher
proportion of those aged 65 years or above (26.2%) achieved
individualised targets, although more people in this age group were
set HbA1c targets of ≥7.5%. The incidence of symptomatic
hypoglycaemia (≤3.9 mmol/L [70 mg/dL]) in the previous 3 months in
SAGE was similar across all age groups (65.7% to 69.6%), while the
incidence of one or more severe hypoglycaemia events in the previ-
ous 6 months increased modestly with age. Across the different
regions analysed, rates of HbA1c target achievement and incidence of
hypoglycaemia varied considerably.
An individual's experience of living with and managing T1DM
may impact glycaemic and hypoglycaemic outcomes. Diabetes-related
emotional distress is an increasingly recognised barrier to the achieve-
ment of optimal glucose control.5 Health-related QoL (HRQoL) has
also been inversely associated with HbA1c levels in people with
T1DM2,6; however, the correlation between HbA1c levels and the
results of the 36-item Short-Form (SF-36), a generic HRQoL question-
naire, is weak at best.2,7 In contrast, diabetes-specific QoL, as mea-
sured by the Audit of Diabetes-Dependent Quality of Life (ADDQoL)
questionnaire, was independently associated with glycaemic control.7
Fear of hypoglycaemia (itself associated with an increase in
incident severe hypoglycaemia and the frequency of symptomatic
hypoglycaemia), and increased body mass index (BMI) have also both
been associated with significant reductions in QoL in people living
with T1DM.8
In the present study, we aimed to evaluate the association
between diabetes-specific PROs and glycaemic control in adults aged
≥26 years with T1DM participating in SAGE, according to age group
and across five world regions.
2 | MATERIALS AND METHODS
2.1 | Study design and participants
This report presents the results of a secondary analysis of the SAGE
study. SAGE was a multinational, cross-sectional, observational study
conducted in 17 countries across Asia (India, Japan and Thailand), East-
ern Europe (Bulgaria, Croatia, Serbia and Ukraine), Latin America
(Argentina, Brazil, Chile and Colombia), the Middle East (Iran and Saudi
Arabia) and Western Europe (France, Germany, Italy and the United
Kingdom). The study methods have been described previously in detail.3
Briefly, adults aged ≥26 years who had T1DM for ≥1 year, were being
treated with insulin, and had an HbA1c value available were enrolled at
one of 230 centres, which were each expected to see ≥100 people with
T1DM each year. Between January and December 2018, data were col-
lected from patient medical records and interviews during a single physi-
cian visit (endocrinologist, general practitioner and other physicians
familiar with the management of people with T1DM). Participants were
asked to complete paper PRO questionnaires during this visit, with
translated and linguistically validated versions of the questionnaires
used in each country. No interventions or investigations were per-
formed for the purposes of this study. All participants provided written
informed consent. The study was undertaken according to local regula-
tory requirements, including Institutional Review Board and Indepen-
dent Ethics Committee approval where appropriate, and was conducted
in accordance with the Declaration of Helsinki and the International
Conference on Harmonization guidelines for Good Clinical Practice.
2.2 | Outcomes
The primary endpoint of the SAGE study was to evaluate the percent-
age of participants achieving HbA1c <7% in each predefined age group
(26-44, 45-64 and ≥65 years). Secondary endpoints included PRO eval-
uations, which are the focus of the present analysis. The association
between PRO scores and glycaemic control, based on the achievement
of both a general HbA1c target of <7% and individualised HbA1c targets
as defined by the treating physician, were also analysed.
2.2.1 | PRO questionnaires
The PROs were assessed using a series of questionnaires, described
below. Specific details of the scoring and interpretation of these ques-
tionnaires is provided in Table S1.
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1. Hypoglycemia Fear Survey-II (HFS-II). This is used to assess fear of
hypoglycaemia with the behaviour subscale (HFS-B), which mea-
sures hypoglycaemia avoidance behaviours, and the worry sub-
scale (HFS-W), which measures worry about hypoglycaemia.
Higher scores indicate a greater tendency to avoid hypoglycaemia
and greater worry regarding hypoglycaemia, respectively. The sum
of the two subscale scores provides the HFS-II total score.
2. Problem Areas In Diabetes (PAID) questionnaire. This is used to
assess emotional status. This questionnaire describes negative
emotions commonly experienced by those with diabetes, with
higher scores indicating a higher level of diabetes-related emo-
tional distress.
3. Insulin Treatment Satisfaction Questionnaire (ITSQ). This was used
to assess satisfaction with current insulin treatment and how it
affects patients' daily lives. It comprises five subscales (inconve-
nience of regimen, lifestyle flexibility, hypoglycaemic control,
glycaemic control, insulin delivery device satisfaction). Higher
scores indicate better treatment satisfaction.
4. Audit of Diabetes-Dependent Quality of Life (ADDQoL) question-
naire. This is used to assess diabetes-specific QoL, whereby the
participant's perceptions of the impact of diabetes on their QoL is
assessed. The questionnaire comprises 19 items, which measures
participant perceptions of the impact of diabetes on specific
aspects of their life, and the importance of these aspects on their
QoL (higher scores reflecting greater positive impact of diabetes).
A further two overview items measure both present QoL (over-
view item 1) and how QoL would be without diabetes (overview
item 2). Higher scores on overview item 1 indicate greater present
QoL; lower scores on overview item 2 indicate better potential
QoL without diabetes.
2.3 | Data analysis and statistics
Statistical analyses were performed using SAS version 9.4. All analyses
were conducted using data from the eligible population; that is, partic-
ipants meeting the inclusion criteria and none of the exclusion criteria,
using descriptive statistics for the overall population and participants
within each predefined age group. The definition of eligible partici-
pants was extended to include those with an HbA1c value within the
previous 45 days (previously 30 days) or with an HbA1c assessment
that was due as part of routine practice in the following 15 days (pre-
viously 7 days).
The relationship between glycaemic control and PRO scores
(HFS-W subscale score [to assess the impact of worry about
hypoglycaemia], PAID total score, ITSQ total and five subscale scores,
ADDQoL total and two overview item scores) were analysed in the
overall population and by age group. Multivariable logistic regression
models were performed with glycaemic control (proportion of partici-
pants achieving general HbA1c target <7% and individualized HbA1c
targets) as a dependant variable, and with each PRO score considered
independently as a covariate. Models were first adjusted by region
and predefined age groups, then by the interaction between each
PRO score and age group. Odds ratios (ORs) and 95% confidence
intervals (95% CIs) were determined for an increase of 10 points in
the HFS-W, PAID, and ITSQ scores, and an increase of 1 point in
the three ADDQoL scores. Then, independent multivariable ana-
lyses were conducted to identify possible confounding factors in
the relationship between glycaemic control and each PRO score,
including variables related to sociodemographic factors, diabetes
complications and comorbidities, T1DM treatment or treatment
impacting glycaemia, and structure and process of medical care.
Factors identified as significant confounders were used to adjust
the multivariable analysis for the relationship between glycaemic
control and each PRO score. The significance level was 5% using
two-sided tests or CIs. P values are provided for descriptive pur-
poses only, due to the descriptive nature of this study. No adjust-
ments for multiple comparisons were undertaken.
3 | RESULTS
3.1 | Participants
Overall, 3903 patients were included in SAGE. The eligible population
comprised 3858 patients, of whom 1724 (44.7%) were aged 26 to
44 years, 1512 (39.2%) were aged 45 to 64 years, and 622 (16.1%)
were aged 65 years or above. Participants were enrolled in 17 coun-
tries across five regions: Asia (n = 780), Eastern Europe (n = 996),
Latin America (n = 488), the Middle East (n = 444) and Western
Europe (n = 1150).
Patient characteristics by age and region have been published
previously. Briefly, the mean (standard deviation [SD]) participant age
was 47.4 (14.0) years, and the mean (SD) BMI was 25.2 (4.5) kg/m2
and was similar across the age groups. The mean (SD) duration of dia-
betes was 20.7 (12.6) years, ranging from 15.9 (9.1) years in those
aged 26 to 44 years to 28.8 (15.1) years in those aged 65 years or
above. Overall, 20.6% of participants had a family history of T1DM,
which was similar across the age groups. The mean (SD) BMI was low-
est in Asia (23.3 [4.0] kg/m2) and highest in the Middle East (26.3
[4.8] kg/m2). The mean duration of diabetes was lowest in Asia (16.8
[11.6] years) and highest in Western Europe (23.0 [13.3] years), while
the proportion of participants with a family history of T1DM was
highest in the Middle East (28.1%), Western Europe (25.0%) and Latin
America (24.3%). The use of diabetes technologies was greatest in
Western Europe (insulin pump 42.3%, continuous glucose monitoring
46.4%) and lowest in the Middle East (insulin pump 2.7%, continuous
glucose monitoring 2.5%; Table S2).
3.2 | Patient-reported outcomes
Overall, PRO questionnaires were completed by >99.0% of partici-
pants for the HFS-II total and subscales, 99.5% for the PAID question-
naire, >97.0% for the ITSQ total and subscales, and >99.0% for the
ADDQoL total questionnaire and overview items.
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F IGURE 1 Patient-reported outcome scores by age group (eligible population). A) Hypoglycaemia Fear Survey II (HFS-II), B) Problem Areas in
Diabetes questionnaire (PAID), C) Insulin Treatment Satisfaction Questionnaire (ITSQ), and D) Audit of Diabetes-Dependent Quality of Life
(ADDQoL). HFS-B, Hypoglycaemia Fear Survey II behaviour subscale; HFS-W, Hypoglycaemia Fear Survey II worry subscale; SD, standard
deviation















































































































































F IGURE 2 Patient-reported outcome scores by region (eligible population). A) Hypoglycaemia Fear Survey II (HFS-II), B) Problem Areas in
Diabetes questionnaire (PAID), C) Insulin Treatment Satisfaction Questionnaire (ITSQ), and D) Audit of Diabetes-Dependent Quality of Life
(ADDQoL). HFS-B, Hypoglycaemia Fear Survey II behaviour subscale; HFS-W, Hypoglycaemia Fear Survey II worry subscale; SD, standard
deviation
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3.2.1 | Hypoglycaemia fear
The mean [SD] HFS-II total score, (38.59 [22.11]), HFS-W score
(20.96 [14.73]) and HFS-B score (17.63 [10.23]) were similar across
the age groups (Figure 1). HFS-II total and subscale scores were low-
est in Asia (Figure 2).
3.2.2 | Diabetes distress
The mean (SD) PAID total score was 32.47 (21.48). Similar results
were observed in the 26 to 44 years (33.77 [21.45]) and 45 to
64 years (32.28 [21.29]) age groups, while participants aged 65 years
or above had the lowest score (29.35 [21.72]; Figure 1). Across the
regions, PAID scores were lowest in Western Europe (28.73 [20.76]),
and highest in the Middle East (39.97 [23.73]; Figure 2).
3.2.3 | Treatment satisfaction
For insulin treatment satisfaction, the mean (SD) ITSQ total score was
69.14 (17.86). High levels of satisfaction were observed across all
ITSQ subscales, with the highest score in the delivery system subscale
(75.35 [21.47]), while the lowest score was in the lifestyle sub-
scale (61.91 [25.64]), in the overall population. For all ITSQ scores,
there was a slight trend for increasing level of satisfaction with
increasing age (Figure 1). When considering the regions, ITSQ total
scores were the highest in Eastern and Western Europe (70.46
[17.47] and 71.64 [16.51]) compared with other regions (Figure 2).
3.2.4 | Impact of diabetes on QoL
The mean total score for ADDQoL was 2.22 (1.78), with comparable
results across age groups (Figure 1). In the overall population, the
score for overview item 1, which assessed present QoL was 0.74
(1.20), while the score for overview item 2, which specifically assessed
how QoL would be without diabetes, was 1.55 (1.06). Similar pat-
terns for ADDQoL scores were observed across all regions except the
Middle East, where total and overview item 2 scores were highest,
while overview item 1 score was lowest (Figure 2).
3.3 | Relationship between PRO scores and
glycaemic target achievement
Relationships between the proportion of participants achieving
HbA1c <7% and each PRO score, adjusted by region and age group,
are presented in Figure 3A. In the overall population, achievement of
HbA1c target <7% was significantly associated with lower HFS-W
scores (OR 0.94 [95% CI 0.89 to 0.99]), lower PAID scores (OR 0.90
[95% CI 0.87 to 0.93]), and higher scores in the ITSQ total (OR 1.15
[95% CI 1.10 to 1.20]) and all subscales except for lifestyle. The
strongest association was observed between HbA1c target achieve-
ment and the ITSQ glycaemic control subscale (OR 1.25 [95% CI 1.20
to 1.29]). HbA1c <7% achievement was also associated with higher
ADDQoL total (OR 1.05 [95% CI 1.01 to 1.10]) and overview item
1 (present QoL) scores (OR 1.13 [95% CI 1.06 to 1.21]), whereas there
was no significant association with ADDQoL overview item 2 (poten-
tial QoL without diabetes) scores.
Relationships between the proportion of patients achieving
physician-defined individualised HbA1c targets and each PRO score,
adjusted by age and region, are presented in Figure 3B. In the overall
population, individualised target achievement was significantly associ-
ated with lower PAID scores (OR 0.93 [95% CI 0.89 to 0.97]), and
higher scores in the ITSQ total (OR 1.11 [95% CI 1.06 to 1.16]) and all
subscales except for lifestyle. Similar to the result for general
glycaemic control, the strongest relationship between ITSQ score and
individualised target achievement was observed for the glycaemic
control subscale (OR 1.21 [95% CI 1.16 to 1.25]). No association was
observed between individualised target achievement with HFS-W and
ADDQoL scores in the overall population.
After adjustment for the interaction between PRO scores and age
group, there was no significant impact of age on the relationship
between general glycaemic control and any of the PRO scores
(P > 0.05; Figure 3A). However, for the relationship between
individualised glycaemic control and PRO scores (Figure 3B), a signifi-
cant impact of age was demonstrated for ITSQ inconvenience and
delivery system subscales (P = 0.045 and P = 0.030, respectively) and
ADDQoL overview item 2 (P = 0.018). With higher ITSQ inconve-
nience and delivery system scores, the likelihood of achieving
individualised targets increased with age. Higher ADDQoL overview
item 2 scores in the age group 26 to 44 years were more likely to be
associated with individualised target achievement compared with
older age groups (Figure 3B).
After adjustment for possible confounders (Table S3), the associa-
tion between HbA1c <7% achievement and higher ITSQ total score
remained significant. Similar results were observed for ITSQ inconve-
nience, hypoglycaemic control, glycaemic control, and delivery system
scores (Figure 4A). The association between HbA1c <7% achievement
and lower PAID scores also remained significant. After adjustment for
possible confounders (Table S4), the associations between
individualised target achievement with ITSQ total, inconvenience, and
glycaemic control scores, as well as PAID scores remained significant
(Figure 4B). However, associations between individualised target
achievement with higher ITSQ hypoglycaemic control and delivery
system subscale scores were no longer significant after adjustment for
possible confounders.
4 | DISCUSSION
In this analysis of the global SAGE study, PRO scores showed rela-
tively low levels of diabetes-related emotional distress and fear of
hypoglycaemia, moderate to high treatment satisfaction, and low
diabetes-related impact on QoL, across the study populations. When
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HFS-W
  26–44 years of age
  45–64 years of age
≥65 years of age
PAID
  26–44 years of age
  45–64 years of age
≥65 years of age
ITSQ total
  26–44 years of age
  45–64 years of age
≥65 years of age
ITSQ inconvenience
  26–44 years of age
  45–64 years of age
≥65 years of age
ITSQ lifestyle
  26–44 years of age
  45–64 years of age
≥65 years of age
ITSQ hypoglycaemic control
  26–44 years of age
  45–64 years of age
≥65 years of age
ITSQ glycaemic control
  26–44 years of age
  45–64 years of age
≥65 years of age
ITSQ delivery system
  26–44 years of age
  45–64 years of age
≥65 years of age
ADDQoL total
  26–44 years of age
  45–64 years of age
≥65 years of age
ADDQoL overview item 1
  26–44 years of age
  45–64 years of age
≥65 years of age
ADDQoL overview item 2
  26–44 years of age
  45–64 years of age
≥65 years of age
Adjusted OR (95% CI)
0.94 (0.89 to 0.99)
0.93 (0.86 to 1.00)
0.97 (0.89 to 1.05)
0.95 (0.83 to 1.08)
Score by age interaction: p=0.764
0.90 (0.87 to 0.93)
0.90 (0.85 to 0.94)
0.91 (0.85 to 0.97)
0.90 (0.82 to 0.99)
Score by age interaction: p=0.946
1.15 (1.10 to 1.20)
1.13 (1.06 to 1.20)
1.16 (1.08 to 1.25)
1.20 (1.06 to 1.35)
Score by age interaction: p=0.650
1.09 (1.05 to 1.13)
1.07 (1.03 to 1.13)
1.08 (1.03 to 1.15)
1.18 (1.07 to 1.30)
Score by age interaction: p=0.262
1.00 (0.97 to 1.03)
0.97 (0.93 to 1.01)
1.03 (0.98 to 1.08)
1.02 (0.95 to 1.10)
Score by age interaction: p=0.189
1.07 (1.03 to 1.11)
1.06 (1.00 to 1.11)
1.07 (1.01 to 1.14)
1.11 (1.01 to 1.22)
Score by age interaction: p=0.682
1.25 (1.20 to 1.29)
1.25 (1.18 to 1.32)
1.25 (1.17 to 1.33)
1.24 (1.11 to 1.38)
Score by age interaction: p=0.988
1.07 (1.03 to 1.11)
1.04 (0.99 to 1.10)
1.08 (1.02 to 1.15)
1.13 (1.02 to 1.25)
Score by age interaction: p=0.329
1.05 (1.01 to 1.10)
1.08 (1.01 to 1.15)
1.03 (0.96 to 1.10)
1.03 (0.91 to 1.16)
Score by age interaction: p=0.578
1.13 (1.06 to 1.21)
1.15 (1.05 to 1.26)
1.11 (1.00 to 1.24)
1.13 (0.96 to 1.33)
Score by age interaction: p=0.902
1.06 (0.98 to 1.14)
1.10 (1.00 to 1.21)
1.00 (0.89 to 1.14)
1.04 (0.85 to 1.26)














































Adjusted OR (95% CI)
0.97 (0.91 to 1.02)
0.98 (0.90 to 1.06)
0.95 (0.87 to 1.05)
0.97 (0.85 to 1.10)
Score by age interaction: p=0.919
0.93 (0.89 to 0.97)
0.94 (0.89 to 0.99)
0.91 (0.86 to 0.98)
0.93 (0.86 to 1.02)
Score by age interaction: p=0.837
1.11 (1.06 to 1.16)
1.06 (0.99 to 1.14)
1.14 (1.06 to 1.24)
1.16 (1.04 to 1.30)
Score by age interaction: p=0.226
1.05 (1.02 to 1.09)
1.01 (0.97 to 1.07)
1.07 (1.01 to 1.13)
1.16 (1.05 to 1.27)
Score by age interaction: p=0.045
1.00 (0.97 to 1.03)
0.97 (0.93 to 1.02)
1.04 (0.98 to 1.09)
1.00 (0.93 to 1.07)
Score by age interaction: p=0.183
1.04 (1.00 to 1.08)
1.01 (0.96 to 1.07)
1.07 (1.00 to 1.14)
1.06 (0.97 to 1.16)
Score by age interaction: p=0.399
1.21 (1.16 to 1.25)
1.18 (1.12 to 1.25)
1.24 (1.16 to 1.33)
1.20 (1.09 to 1.33)
Score by age interaction: p=0.596
1.04 (1.00 to 1.08)
1.00 (0.94 to 1.05)
1.05 (0.99 to 1.12)
1.16 (1.05 to 1.28)
Score by age interaction: p=0.030
1.03 (0.98 to 1.08)
1.06 (0.99 to 1.13)
1.01 (0.94 to 1.09)
0.98 (0.87 to 1.10)
Score by age interaction: p=0.450
1.03 (0.96 to 1.10)
1.04 (0.94 to 1.14)
1.03 (0.92 to 1.16)
1.00 (0.85 to 1.16)
Score by age interaction: p=0.912
1.03 (0.95 to 1.12)
1.15 (1.03 to 1.28)
0.92 (0.81 to 1.05)
0.93 (0.77 to 1.12)



















































Adjusted OR (95% CI)
0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4
F IGURE 3 Relationship between glycaemic control (A, proportion of participants achieving glycated haemoglobin [HbA1c] <7% and B,
proportion of participants achieving their individualised HbA1c target) and each patient-reported outcome score (eligible population). Adjusted
odds ratios, 95% confidence intervals (CIs) and P values based on logistic regression with glycaemic control (proportion of patients achieving
HbA1c <7%) as a dependent variable, with each score considered independently as a covariate, adjusted by region and predefined age groups.
ADDQoL, Audit of Diabetes-Dependent Quality of Life; HFS-W, Hypoglycaemia Fear Survey II worry subscale; ITSQ, Insulin Treatment
Satisfaction Questionnaire; PAID, Problem Areas in Diabetes questionnaire
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considering present QoL specifically, the global score indicated a neu-
tral impact of diabetes.
Multivariable analyses indicated that lower diabetes-related emo-
tional distress and higher insulin treatment satisfaction reported
by patients are associated with achievement of both general
(HbA1c <7%) and individualized HbA1c targets. Relatively low levels
of diabetes-related distress have previously been observed in adults
with T1DM,9–11 although a study including participants with T1DM
and T2DM did identify 45% of participants as having “high distress”
using a cut-off score of ≥40 on the PAID scale.12 Similar to SAGE,
other studies have reported a significant association between higher
levels of distress and worse glycaemic control.10,11,13 For diabetes
treatment satisfaction, high scores on the ITSQ assessment have been
reported regardless of previous insulin delivery system used,14
although satisfaction has also been shown to improve with use of
insulin pump versus multiple daily injections.15 Other analyses have
shown poor diabetes-related satisfaction to be associated with higher
HbA1c levels in adults and adolescents,16,17 supporting the results
from SAGE. Notably in SAGE, the association between target
achievement and treatment satisfaction was particularly strong for
the ITSQ glycaemic control subscale, which specifically evaluates the
patient's satisfaction with their insulin treatment to control glucose
levels.
In contrast to the multivariable analysis of distress and treatment
satisfaction, lower worry about hypoglycaemia and higher ADDQoL
total scores (lower impact of diabetes on QoL) were only associated
with achievement of the general HbA1c target, but these relationships
disappeared after adjusting for confounders. The lack of association
between worry of hypoglycaemia and individualised target achieve-
ment could reflect the higher HbA1c levels set as individualised tar-
gets (mostly 7.0%-7.5%), particularly in the older age groups.
Experiencing severe hypoglycaemia has previously been shown to be
associated with increased hypoglycaemia fear scores,8,18 and the rela-
tively low fear of hypoglycaemia observed in SAGE could conceivably
reflect the perception that less intensive HbA1c targets reduce
the risk of hypoglycaemia. However, the association between
hypoglycaemia events and PROs was not assessed in SAGE, and it is
important to note that the relationship between HbA1c levels and




ITSQ hypoglycaemic control score
ITSQ glycaemic control score
ITSQ delivery system score
ITSQ total score
PAID score
Adjusted OR (95% CI)
1.07 (0.99 to 1.15)
1.01 (0.96 to 1.05)
0.96 (0.91 to 1.02)
1.07 (1.03 to 1.11)
1.06 (1.02 to 1.10)
1.24 (1.19 to 1.29)
1.04 (1.00 to 1.09)
1.14 (1.09 to 1.19)





















Relationship with glycaemic control
considering confounding factors†
(A)
Adjusted OR (95% CI)
0.8 0.9 1.0 1.1 1.2 1.3
ITSQ inconvenience score
ITSQ hypoglycaemic control score
ITSQ glycaemic control score
ITSQ delivery system score
ITSQ total score
PAID score
Adjusted OR (95% CI)
1.05 (1.01 to 1.09)
1.03 (0.99 to 1.07)
1.20 (1.16 to 1.25)
1.03 (0.99 to 1.08)
1.10 (1.05 to 1.16)















Relationship with glycaemic control
considering confounding factors‡
(B)
Adjusted OR (95% CI)
0.8 0.9 1.0 1.1 1.2 1.3
F IGURE 4 Relationship between glycaemic control (A, proportion of participants achieving glycated haemoglobin [HbA1c] <7% and B,
proportion of participants achieving individualised HbA1c target) and patient-reported outcome (PRO) scores (eligible population), adjusted for
confounding factors. Odds ratio (OR) for an increase of 10 points in the Hypoglycaemia Fear Survey II worry subscale (HFS-W), Problem Areas in
Diabetes questionnaire (PAID) and Insulin Treatment Satisfaction Questionnaire (ITSQ) scores and OR for an increase of 1 point in the Audit of
Diabetes-Dependent Quality of Life (ADDQoL) scores, based on multivariate logistic analysis with confounding factors considered in the model.
†See Table S3 for confounding factors identified for relationship between glycaemic control (proportion of participants with T1DM achieving
HbA1c <7%) and PRO scores.
‡See Table S4 for confounding factors identified for relationship between glycaemic control (proportion of people
with T1DM achieving individualised HbA1c target) and PRO scores. CI, confidence interval
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hypoglycaemia is nonlinear, with both particularly low and high levels
having been linked with a greater risk of hypoglycaemia.19 Also reflecting
results from SAGE, ADDQoL scores showing overall neutral general
QoL, and a relatively low negative impact of diabetes, have been
reported in adults with T1DM.20 Although some gender differences on
specific domains of the ADDQoL were observed, only the presence of
diabetes complications was found to be a significant predictor of lower
QoL in the study, whereas factors including age, BMI and HbA1c were
not.20 Similarly, this analysis of SAGE showed no association between
ADDQoL and HbA1c target achievement after adjusting for potential
confounders including age and BMI, therefore HbA1c control may not
be relevant for how people living with diabetes perceive the impact of
diabetes on their QoL. This lack of correlation between HbA1c and QoL
has been reported elsewhere,21 but other studies provide conflicting
results showing a significant inverse relationship between HbA1c and
QoL, in both adults and children.1,2,6,22
Patient-reported outcomes and their association with glycaemic
control may be affected by age and regional differences in T1DM man-
agement as well as cultural perceptions and healthcare system-related
factors, including access to newer therapies and technologies. Some dif-
ferences across age groups and regions in participant education levels,
employment, health insurance and technology use were described in the
primary SAGE report.3 However, PRO scores were generally comparable
across age groups, while more variability was observed among regions.
Discrepancies between the actual experience of hypoglycaemia or target
achievement, and the PROs related to these factors, could reflect differ-
ences in healthcare access and diabetes education,12,23 which may
impact how individuals understand hypoglycaemia and treatment suc-
cess. However, it is important to note that any regional differences
reported in this study are purely descriptive.
This analysis of the SAGE study provides insights into PROs and
their relationship with glycaemic control, in a large international popula-
tion of adults with T1DM. The analysis shows surprisingly consistent
PRO results, despite the large variability of healthcare systems across the
regions. Nevertheless, there is a lack of representation from North Amer-
ica, Africa, and even certain countries within each analysed region.
Another limitation is the cross-sectional design of the study, which does
not allow for any temporal or directional association between PROs and
glycaemic control to be determined. Furthermore, any interpretation of
the results must consider the healthy survivor effect, particularly in the
older age group. This selection bias may further limit how representative
the study population is of patients in each region.
In conclusion, this analysis of the SAGE study indicates people
with T1DM reported a relatively low impact of diabetes on
hypoglycaemia fear, emotional distress and QoL, and a moderate to
high insulin treatment satisfaction, despite suboptimal glycaemic con-
trol observed in populations across regions and age groups. Better
glycaemic control was most closely associated with patient-reported
insulin treatment satisfaction (especially satisfaction in the ability of
their insulin treatment to control their blood glucose levels) and low
emotional distress due to diabetes; therefore, better understanding of
how PROs and levels of glycaemic control influence each other may
help improve the management of adults with T1DM.
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